Clinical trial
A Randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SYS6010 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma Who Have Failed at Least One Line of Systemic Therapy.
NCT07417735 is registered in ClinicalTrials.gov with CSPC Megalith Biopharmaceutical Co.,Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SYS6010 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma Who Have Failed at Least One Line of Systemic Therapy.
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- March 18, 2026
- Completion date
- December 31, 2029
- Enrollment
- 436 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced/metastatic/recurrent escc